Live Webcast from the Millennium Broadway Hotel in New York on Thursday,
SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that John P. Longenecker, Ph.D., President and Chief Executive Officer, will present at the NewsMakers in the Biotech Industry investment conference at 9:00 a.m. Eastern time on Thursday, September 6, 2007. The conference, presented by BioCentury and Thomson, will be held at the Millennium Broadway Hotel in New York City.
Dr. Longenecker will provide an overview of Favrille and the clinical trials of its lead compound, FavId(R), which is currently in a pivotal Phase 3 clinical trial for the treatment of follicular B-cell non-Hodgkin's lymphoma (NHL). A live webcast of the presentation can be accessed at http://www.favrille.com. The replay will be available approximately one hour after the presentation and will be archived until October 6, 2007.
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the
development and commercialization of targeted immunotherapies for the
treatment of cancer and other diseases of the immune system. The Company's
lead product candidate, FavId, is based upon unique genetic information
extracted from a patient's tumor. FavId is currently under investigation in
a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL
and Phase 2 clinical trials in other B-cell NHL indications. The Company is
developing additional applications based on its immunotherapy expertise and
proprietary cost-effective manufacturing technology, including a second
|SOURCE Favrille, Inc.|
Copyright©2007 PR Newswire.
All rights reserved